Neurotrauma Reports (Mar 2024)

Cognitive and Motor Function Effects of Antipsychotics in Traumatic Brain Injury: A Systematic Review of Pre-Clinical Studies

  • Gabrielle Cataford,
  • Laurie-Anne Monton,
  • Stephanie Karzon,
  • Camille Livernoche-Leduc,
  • Mar Saavedra-Mitjans,
  • Marie-Julie Potvin,
  • Francis Bernard,
  • Lisa Burry,
  • Caroline Arbour,
  • David R. Williamson

DOI
https://doi.org/10.1089/NEUR.2023.0108
Journal volume & issue
Vol. 5, no. 1
pp. 181 – 193

Abstract

Read online

Traumatic brain injury (TBI) survivors often suffer from agitated behaviors and will most likely receive pharmacological treatments. Choosing an optimal and safe treatment that will not interfere with neurological recovery remains controversial. By interfering with dopaminergic circuits, antipsychotics may impede processes important to cognitive recovery. Despite their frequent use, there have been no large randomized controlled studies of antipsychotics for the management of agitated behaviors during the acute TBI recovery period. We conducted a systematic review and meta-analysis of pre-clinical studies evaluating the effects of antipsychotics post-TBI on both cognitive and motor recovery. MEDLINE and Embase databases were searched up to August 2, 2023. Pre-clinical studies evaluating the effects of antipsychotics on cognitive and motor functions post-TBI were considered. Risk of bias was evaluated with the Systematic Review Centre for Laboratory Animal Experimentation (SYRCLE) tool. We identified 15 studies including a total of 1188 rodents, mostly conducted in male Sprague-Dawley rats using cortical impact injury. The analysis revealed no consistent effect of haloperidol on motor functions, but risperidone was associated with a significant impairment in motor function on day 5 post-injury (7.05?sec; 95% confidence interval [CI]: 1.47, 12.62; I2?=?92%). Other atypical antipsychotics did not result in impaired motor function. When evaluating cognitive function, haloperidol- (23.00?sec; 95% CI: 17.42?28.59; I2?=?7%) and risperidone-treated rats (24.27?sec; 95% CI: 16.18?32.36; I2?=?0%) were consistently impaired when compared to controls. In studies evaluating atypical antipsychotics, no impairments were observed. Clinicians should avoid the regular use of haloperidol and risperidone, and future human studies should be conducted with atypical antipsychotics.

Keywords